Company Overview and News

 
Tapping sunshine: Tata Power aims to grow solar rooftop business four-times in four years

12h financialexpress
Tata Power Renewable Energy, the wholly-owned subsidiary of Tata Power Company, plans to grow its rooftop business four-fold to around 1,000 MW from present 250 MW in next three to four years, even as the company plans awareness campaigns in 100 cities by end of FY19.
TATAPOWER TPCL 500400

 
Gujarat relief for Tata Power, Adani Power underlines sector’s harsh reality

2018-10-14 livemint
Shares of Tata Power Co. Ltd and Adani Power Ltd rallied 8-10% on Friday after the Gujarat government submitted a report to the Supreme Court, suggesting relief for companies running imported coal-based power plants.
TATAPOWER 533096 TPCL 500400 ADANIPOWER

 
Reliance Power’s market cap falls by 93.3% since IPO

2018-10-13 financialexpress
The market cap of Anil Ambani-led Reliance Power, one of the major private power producers in the country, has fallen by 93.3% since its IPO in 2008.
RPOWER 532939 TATAPOWER 533096 ATB TPCL 500400 ADANIPOWER JSWENERGY 533148

 
Imported coal-based power plants: SC to hear Gujarat’s plea

2018-10-13 financialexpress
The Supreme Court will take up the Gujarat government’s petition, seeking to implement a high-power committee’s recommendations aimed at salvaging imported-coal-based power projects in the state on October 29.
533096 TATAPOWER TPCL 500400 ADANIPOWER

 
Sadbhav Engg, Jai Corp, Jyothy Labs, Navkar Corp, Tata Power top gainers among BSE Group A stocks

2018-10-12 moneycontrol
The Indian benchmark indices extended the morning gains with the Nifty50 rallying 243 points, trading at 10,478 while the Sensex zoomed over 737 points at 34,742.
530299 PGEL JYOTHYLAB KOTHARIPRO 532926 TATAPOWER 533581 TPCL 500400 SADBHAV 532710

 
Panel#39;s recommendations may bring Rs 1.29 lakh cr relief to Gujarat#39;s 3 stranded power projects

2018-10-11 moneycontrol
The recommendations of a high-powered committee on stranded power projects set up by the Gujarat government can bring a combined relief of Rs 1.29 lakh crore for Tata, Adani and Essar's power plants in the state over the next 30 years, according to a source.
TATAPOWER TPCL 500400

1
Tata Power among bidders in race for Odisha’s CESU

2018-10-11 livemint
New Delhi: Tata Power Co. Ltd. is among two bidders in the race to acquire Central Electricity Supply Utility of Odisha (CESU Odisha) in what would be the first such deal in nearly two decades in India’s power sector.
RELEY TATAPOWER RIFS 539254 RELFF 500390 RELINFRA TPCL RIFA 500400 AES ADANITRANS

 
Whopping Rs 1 lakh crore NPA resolution of stressed power projects possible; banks’ haircut to be this much

2018-10-10 financialexpress
A successful resolution of non-performing assets worth Rs 1 lakh crore in coal-based power projects is possible with a 40%-60% haircut, a report has said. India’s coal-based power projects are staring at least Rs 3.8 lakh crore worth of NPAs.
TATAPOWER TPCL 500400 SBAZ

 
Tata Steel’s next acquisition gets a step closer; Usha Martin seeks shareholders’ nod for deal

2018-10-10 financialexpress
After the successful acquisition of Bhushan Steel, Tata Steel’s plan of acquiring steel business of Usha Martin Ltd (UML) got a step closer, with the latter looking to seek shareholders’ approval for the deal. UML on Wednesday said that it will seek shareholders’ nod with regard to the sale of its steel business to Tata Steel, news agency PTI reported.
USHAMART 517146 500470 TTST TATASTEEL TATLY BHUSANSTL UHBTY TATAPOWER TPCL 500400 500055

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...